<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01134341</url>
  </required_header>
  <id_info>
    <org_study_id>PDX-018</org_study_id>
    <nct_id>NCT01134341</nct_id>
  </id_info>
  <brief_title>Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma</brief_title>
  <official_title>A Phase 1, Open-label, Dose-finding Study of Pralatrexate Plus Systemic Bexarotene in Patients With Relapsed or Refractory Cutaneous T Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spectrum Pharmaceuticals, Inc</source>
  <brief_summary>
    <textblock>
      This study is designed to determine the recommended dose, safety, pharmacokinetics, and early
      efficacy of the combination of pralatrexate plus oral bexarotene in patients with relapsed or
      refractory CTCL.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT) Rate</measure>
    <time_frame>Assessed weekly through cycle 1 (weeks 1-4)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Assessed after every 2 cycles (8 weeks) for the first 12 months, then every 4 cycles (16 weeks) until progression of disease.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Treatment-related Adverse Events (AEs) and Serious AEs (SAEs)</measure>
    <time_frame>Recorded at all study visits: weekly (every 7 +/- 2 days) while on treatment and at safety follow-up (35 +/- 5 days post-last dose) or early termination visit (at time of withdrawal).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters</measure>
    <time_frame>Sampling through 24 hours post end-injection of pralatrexate in cycle 1 dose 1 (week 1) and cycle 1 dose 3 (week 3).</time_frame>
    <description>This was collected during the dose-finding stage of the study. PK sampling is not included in the cohort expansion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Cutaneous T-cell Lymphoma</condition>
  <condition>Mycosis Fungoides</condition>
  <condition>Sezary Syndrome</condition>
  <condition>Primary Cutaneous Anaplastic Large Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Pralatrexate &amp; Bexarotene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pralatrexate Injection</intervention_name>
    <description>Intravenous (IV) push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline (0.9% sodium chloride).
10 or 15 mg/m2, depending on cohort assignment.
Dose reductions allowed for protocol-specified criteria.
Administered weekly for 3 weeks of 4-week cycle (weekly for 3 weeks with one week of rest) until criteria for discontinuation per the protocol are met.</description>
    <arm_group_label>Pralatrexate &amp; Bexarotene</arm_group_label>
    <other_name>FOLOTYN</other_name>
    <other_name>PDX</other_name>
    <other_name>Pralatrexate</other_name>
    <other_name>(RS)-10-propargyl-10-deazaaminopterin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bexarotene Capsules</intervention_name>
    <description>150 or 300 mg orally, depending on cohort assignment. Provided as 75 mg capsules and taken with a meal.
Dose reductions allowed for protocol-specified criteria and implemented per the Targretin® package insert.
Administered daily until criteria for study treatment discontinuation per the protocol are met.</description>
    <arm_group_label>Pralatrexate &amp; Bexarotene</arm_group_label>
    <other_name>Bexarotene</other_name>
    <other_name>Targretin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin B12</intervention_name>
    <description>1 mg intramuscular injection
Administered within 10 weeks prior to start of study treatment, every 8-10 weeks throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene).</description>
    <arm_group_label>Pralatrexate &amp; Bexarotene</arm_group_label>
    <other_name>Cyanocobalamin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Folic Acid</intervention_name>
    <description>1-1.25 mg orally
Administered daily for at least 7 days prior to start of study treatment, throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene).</description>
    <arm_group_label>Pralatrexate &amp; Bexarotene</arm_group_label>
    <other_name>Vitamin B9</other_name>
    <other_name>Folate</other_name>
    <other_name>Folacin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cutaneous T-cell lymphoma patients with subtypes of mycosis fungoides (MF) Stage IB or
             higher, Sézary syndrome, or primary cutaneous anaplastic large cell lymphoma who have
             failed a previous systemic treatment.

          -  Patients must have received at least 1 previous systemic therapy, and either
             progressed or not tolerated their last prior treatment regimen.

          -  Eastern Cooperative Oncology Group Performance Status less than or equal to 2.

          -  Adequate blood, liver, and kidney function as defined by laboratory tests.

          -  Women of childbearing potential must practice medically acceptable contraception from
             study treatment start until at least 30 days after the last dose of study treatment.
             Negative serum pregnancy test within 14 days before the first day of study treatment
             (not required for patients who are postmenopausal for at least 1 year or surgically
             sterilized). Study treatment should not be given to women who are breastfeeding.

          -  Males who are sexually active must agree to practice medically acceptable barrier
             contraception while receiving study treatment and for 30 days after the last dose of
             study treatment.

          -  Give written informed consent &amp; privacy authorization.

        Exclusion Criteria:

          -  If there is a history of prior malignancies other than non-melanoma skin cancer,
             carcinoma in situ of the cervix, localized prostate cancer, or localized thyroid
             cancer, patient must be disease free for at least 5 years. Patients with other prior
             malignancies less than 5 years before study entry may be enrolled if they received
             treatment resulting in complete resolution of the cancer and have no current clinical,
             radiologic, or laboratory evidence of active or recurrent disease.

          -  Human immunodeficiency virus (HIV)-positive diagnosis with a CD4 count of less than
             100 mm3 or detectable viral load within the past 3 months, and receiving combination
             anti-retroviral therapy.

          -  Diagnosis of Hepatitis B virus, or Hepatitis C virus with detectable viral load or
             immunological evidence of chronic active disease or receiving/requiring antiviral
             therapy.

          -  Active central nervous system disease requiring treatment.

          -  Active uncontrolled infection, underlying medical condition, or other serious illness
             impairing the patient's ability to receive protocol treatment.

          -  Discontinuation of prior oral bexarotene due to an allergic reaction or
             treatment-related toxicity.

          -  Major surgery within 2 weeks of planned start of treatment.

          -  Conventional or investigational chemotherapy or radiation therapy encompassing greater
             than 10% of bone marrow within 4 weeks prior to study treatment.

          -  ECP, phototherapy with PUVA, or ultraviolet (UV) therapy within 2 weeks prior to study
             treatment.

          -  Systemic corticosteroids within 3 weeks of study treatment, unless patient has been
             taking a continuous dose of no more than 10 mg per day of prednisone or equivalent for
             at least 4 weeks.

          -  Initiation of or change in dosage of topical corticosteroids within 3 weeks of study
             treatment (topical steroid use within 3 weeks is allowed provided the strength and use
             has been stable for at least 4 weeks).

          -  Investigational drugs, biologics, or devices use within 2 weeks prior to study
             treatment or planned use during the study.

          -  Monoclonal antibody within 3 months without evidence of PD.

          -  Use of oral retinoids, except bexarotene, within 4 weeks of study treatment or
             high-dose vitamin A (once daily multi-vitamin allowed).

          -  Previous exposure to pralatrexate.

          -  Uncontrolled hypercholesterolemia or hypertriglyceridemia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pankaj Sharma, MD</last_name>
    <role>Study Director</role>
    <affiliation>Spectrum Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh School of Medicine</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant'Orsola - Policlinico Sant'Orsola</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2010</study_first_submitted>
  <study_first_submitted_qc>June 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2010</study_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Lymphoma, Primary Cutaneous Anaplastic Large Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Aminopterin</mesh_term>
    <mesh_term>10-deazaaminopterin</mesh_term>
    <mesh_term>Bexarotene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

